您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > Crisaborole
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Crisaborole
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Crisaborole图片
CAS NO:906673-24-3
规格:≥98%
包装与价格:
包装价格(元)
25mg电议
50mg电议
100mg电议
250mg电议
500mg电议
1g电议

产品介绍
理化性质和储存条件
Molecular Weight (MW) 251.05
Formula C14H10BNO3
CAS No. 906673-24-3; 906673-25-4
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: ~50 mg/mL (199.2 mM)
Water: N/A
Ethanol: N/A
SMILES4-((1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)oxy)benzonitrile
SynonymsAN-2728; PF06930164; AN 2728; PF-06930164; AN2728; PF 06930164; trade name: Eucrisa
SMILES CodeN#CC1=CC=C(OC2=CC=C3C(B(O)OC3)=C2)C=C1
实验参考方法
In Vitro

In vitro activity: Crisaborole (AN2728) inhibits PDE4, TNF-α, IL-2, IFN-γ, IL-5 and IL-10 with IC50 values of 0.49, 0.54, 0.61, 0.83, 2.4 and 5.3 μM respectively. Crisaborole exhibits the most potent activity against PDE4 catalytic domain, but it also shows inhibition against PDE1A3, PDE3Cat, and PDE7A1. Crisaborole inhibits PDE isozymes PDE1A3, PDE3Cat , PDE4Cat and PDE7A1 with IC50 values of 6.1, 6.4, 0.11 and 0.73 μM. Crystallography reveals that interaction of benzoxaboroles with the hydrophobic pocket in the PDE4 catalytic domain increase their affinity for PDE4. These benzoxaboroles strongly suppresses the secretion of cytokines associated with Ps and AD. Crisaborole is a topically administered, boron-containing, anti-inflammatory compound that inhibits PDE4 activity and thereby suppresses the release of TNFalpha, IL-12, IL-23 and other cytokines.


Kinase Assay: Crisaborole (AN2728) inhibits PDE4, TNF-α, IL-2, IFN-γ, IL-5 and IL-10 with IC50 values of 0.49, 0.54, 0.61, 0.83, 2.4 and 5.3 μM respectively. Crisaborole exhibits the most potent activity against PDE4 catalytic domain, but it also shows inhibition against PDE1A3, PDE3Cat, and PDE7A1. Crisaborole inhibits PDE isozymes PDE1A3, PDE3Cat , PDE4Cat and PDE7A1 with IC50 values of 6.1, 6.4, 0.11 and 0.73 μM.

In VivoCrisaborole (AN2728) shows significant inhibition against the ear edema caused by phorbol ester after dosing at 1 mg/ear×2 (78% and 68%, respectively). The efficacy is comparable to that of dexamethasone, suggesting that Crisaborole (AN2728) has good anti-inflammatory activity as well as skin penetration. Crisaborole (AN2728) is reported to be well tolerated and to demonstrate significant effects on markers of efficacy, with results that were comparable to positive controls in clinical trials.
Animal modelMale and female (325 each) Crl:CD1(ICR) mice
Formulation & Dosage Formulated in 1% w/v carboxymethylcellulose (CMC); 0, 30, 100, or 300 mg/kg/day; Oral
References J Dermatol Sci. 2017 Aug;87(2):116-122; Curr Opin Investig Drugs. 2009 Nov;10(11):1236-42; Bioorg Med Chem Lett. 2009 Apr 15;19(8):2129-32.